GSK Respiratory OTC Sales Up 13% In Q1
This article was originally published in The Tan Sheet
Executive Summary
Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan
You may also be interested in...
Commit Sales Contribute To 25% Gain In GSK Smoking Cessation Sales In Q4
Sales of GlaxoSmithKline's Commit nicotine polacrilex lozenge helped drive the company's fourth quarter smoking cessation sales to $198 mil., up 25% at constant exchange rates compared with the year-ago period
GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned
GlaxoSmithKline's Phase IV obligations for its Commit nicotine polacrilex lozenge include a study of consumers who are contraindicated for use of the OTC smoking cessation drug due to underlying health conditions, FDA's Oct. 31 approval letter states
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC